Document is current
Any future updates will be listed below
-
Authors
Guegan, Jean Philippe
El Ghazzi, Nathan
Vibert, Julien
Rey, Christophe
Vanhersecke, Lucile
Coindre, Jean Michel
Toulmonde, Maud
Spalato Ceruso, Mariella
Peyraud, Florent
Bessede, Alban
Italiano, Antoine
-
Funding
Funding for this research was provided by:
Agence Nationale de la Recherche (RHU CONDOR, RHU CONDOR, RHU CONDOR, RHU CONDOR, RHU CONDOR)
- License Information
-
More Information
Article History
Received: 26 July 2024
Accepted: 29 September 2024
First Online: 23 October 2024
Declarations
:
: This study was approved by a Central Institutional Review Board (Comité de Protection des Personnes Sud Est II, Lyon, France), according to good clinical practices and applicable laws and regulations. All methods were performed in accordance with the relevant guidelines and regulations. All patients provided written informed consent.
: AB and JPG: Employees of Immusmol/Explicyte. AI: Received research grants from Astra Zeneca, Bayer, BMS, Chugai, Merck, MSD, Pharmamar, Novartis, Roche, and received personal fees from BMS, MSD, Merck, Roche, Epizyme, Bayer, Lilly, Roche, and Springworks. The other authors have nothing to disclose.
